

## ABIRATERONE

---

### Products Affected

- Abiraterone Acetate

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Abiraterone is approved for use in combination with prednisone. The patient must have a history of intolerance or contraindication to Zytiga before abiraterone will be authorized.

# ACITRETIN

---

## Products Affected

- Acitretin

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For initial therapy in the treatment of psoriasis: trial and failure, contraindication, or intolerance to methotrexate or cyclosporine is required. For continuation of therapy, approve if patient has already been started on Acitretin.

# ACTIMMUNE

---

## Products Affected

- Actimmune

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ALIMTA

---

## Products Affected

- Alimta

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	B vs D coverage determination

# ALOSETRON

---

## Products Affected

- Alosetron Hydrochloride

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Alosetron will not be approved for use in men, as safety and efficacy in men has not been established.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Alosetron is considered medically necessary for the treatment of severe IBS-D. At least one of the following must be present for diarrhea to be considered severe: frequent and severe abdominal pain or discomfort, frequent bowel urgency or fecal incontinence, and disability or restriction of daily activities due to IBS.

# AMYLIN ANALOG

---

## Products Affected

- Symlinpen 120
- Symlinpen 60

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Hemoglobin A1C less than 7% prior to initiating Amylin Analog therapy.
<b>Required Medical Information</b>	Documentation of past and current medication history.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	The member must have documentation of previous insulin failure and documentation of continuation of insulin therapy concomitantly with the requested drug.

# ANABOLIC STEROIDS, ANDROGENS

---

## Products Affected

- Anadrol-50
- Oxandrolone TABS
- Testosterone GEL 25MG/2.5GM, 50MG/5GM
- Testosterone Pump GEL 1%

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ANTIFUNGALS, AZOLE

---

## Products Affected

- Voriconazole INJ
- Voriconazole SUSR
- Voriconazole TABS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documented fungal culture and/or notes from medical record suggestive of a serious fungal infection. For prophylactic use, fungal culture and medical records are not required.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 to 6 months, depending on indication
<b>Other Criteria</b>	For the treatment of oropharyngeal candidiasis, the candidiasis must be refractory to itraconazole or fluconazole.



# ANTIFUNGALS, POLYENE

---

## Products Affected

- Abelcet
- Ambisome
- Amphotericin B INJ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	B vs D coverage determination

## ANTIFUNGALS, SUPERFICIAL AND SYSTEMIC

---

### Products Affected

- Caspofungin Acetate
- Itraconazole CAPS
- Itraconazole SOLN

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Onychomycosis (fingernails)-2mo. Onychomycosis (toenails)-3mo. All other indications -12 months
Other Criteria	For the treatment of tinea versicolor or pityriasis, use of oral ketoconazole or a topical antifungal agent is required prior to the use of Itraconazole. For candidiasis infections (unless specified <i>C. glabrata</i> or <i>C. krusei</i> ), use of fluconazole is required prior to the use of itraconazole.

## ANTIFUNGALS, TRIAZOLE

---

### Products Affected

- Noxafil SUSP
- Noxafil TBEC
- Posaconazole Dr

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	<p>For the prophylaxis of invasive Aspergillus and Candida infections: Noxafil (posaconazole) is considered medically necessary in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.</p> <p>For the treatment of oropharyngeal candidiasis, the candidiasis must be refractory to itraconazole or fluconazole.</p>

# ANTINEOPLASTICS, MONOCLONAL ANTIBODIES

---

## Products Affected

- Abraxane
- Aliqopa
- Avastin
- Bavencio
- Besponsa
- Bortezomib
- Cyramza
- Darzalex
- Enhertu
- Gazyva
- Herceptin
- Herceptin Hylecta
- Imfinzi
- Kadcyla
- Kanjinti INJ 420MG
- Keytruda INJ 100MG/4ML
- Lartruvo
- Libtayo
- Lumoxiti
- Mvasi
- Mylotarg
- Opdivo
- Perjeta
- Poteligeo
- Rituxan
- Rituxan Hycela
- Tecentriq
- Unituxin
- Vectibix INJ 100MG/5ML,  
400MG/20ML
- Velcade
- Yervoy
- Yondelis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	B vs D coverage determination

# APOKYN

---

## Products Affected

- Apokyn INJ 30MG/3ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ARCALYST

---

## Products Affected

- Arcalyst

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	12 years of age and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	B vs D coverage determination

# ARIKAYCE

---

## Products Affected

- Arikayce

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-Approved Indications, Some Medically-Accepted Indications.
<b>Off-Label Uses</b>	Cystic fibrosis pseudomonas aeruginosa infection
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, previous medication history
<b>Age Restrictions</b>	MAC-18 years and older
<b>Prescriber Restrictions</b>	MAC-Prescribed by a pulmonologist, infectious disease physician or a physician who specializes in the treatment of MAC lung infections. Cystic fibrosis-prescribed by or in consultation with a pulmonologist or physician who specializes in the treatment of cystic fibrosis
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	MAC Lung disease-approve if the patient has NOT achieved negative sputum cultures for Mycobacterium avium complex after a background multidrug regimen AND Arikayce will be used in conjunction to a background multidrug regimen. Note-a multidrug regimen typically includes a macrolide (azithromycin or clarithromycin), ethambutol and a rifamycin (rifampin or rifabutin). Cystic fibrosis-patient has pseudomonas aeruginosa in culture of the airway.



# AUSTEDO

---

## Products Affected

- Austedo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Chorea associated with Huntington's disease: trial and failure, contraindication, or intolerance to tetrabenazine. For the treatment of tardive dyskinesia, no trial and failure is required

# BANZEL

---

## Products Affected

- Banzel

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# BENLYSTA

---

## Products Affected

- Benlysta INJ 120MG, 400MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Concurrent use with other biologics or with cyclophosphamide intravenous (IV)
<b>Required Medical Information</b>	The patient must have a positive autoantibody test (i.e., anti-nuclear antibody [ANA] greater than or equal to 1:80 and/or anti-double-stranded DNA [anti-dsDNA] greater than or equal to 30 IU/ml).
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	The patient must be receiving one standard therapy for SLE with any of the following: corticosteroids, hydroxychloroquine, or immunosuppressives (cyclophosphamide, azathioprine, mycophenolate, methotrexate, cyclosporine) AND there must be an absence of severe active lupus nephritis or severe active central nervous system lupus before Benlysta is authorized. B vs D coverage determination.

# BEXAROTENE

---

## Products Affected

- Bexarotene

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# BOTOX

---

## Products Affected

- Botox

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Exclude when used for cosmetic purposes.
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Initial: 3 months. Continuation: 12 months
<b>Other Criteria</b>	<p>For chronic migraine, the patient has had failure or inadequate response following a minimum 3 month trial, contraindication per FDA label, intolerance, or not a candidate for at least TWO different prescription migraine prevention therapies from different classes of migraine prophylaxis medications: Antiepileptic drugs (ex: divalproex, sodium valproate, topiramate), Antidepressants (ex: amitriptyline, venlafaxine), Beta blockers (ex:metoprolol, propranolol, timolol, atenolol, nadolol)</p> <p>For overactive bladder, the patient has had failure or inadequate response two antimuscarinic medications for OAB (for example: darifenacin, flavoxate, oxybutynin, solifenacin, tolterodine, Toviaz).</p>

# BRUKINSA

---

## Products Affected

- Brukinsa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved indications not otherwise excluded from Part D
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	Mantle Cell Lymphoma – approve for 3 years if the patient has tried at least one prior therapy.

# BUPRENORPHINE

---

## Products Affected

- Buprenorphine Hcl SUBL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of opioid dependence.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Induction therapy: 1 month. Pregnancy/Hypersensitivity to naloxone: 12 months
<b>Other Criteria</b>	The use of buprenorphine for maintenance therapy should be limited to patients who have experienced a hypersensitivity reaction to naloxone or require buprenorphine during pregnancy.

# CARBAGLU

---

## Products Affected

- Carbaglu

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



# CAYSTON

---

## Products Affected

- Cayston

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of Cystic Fibrosis and documentation of Pseudomonas aeruginosa infection.
<b>Age Restrictions</b>	7 years of age and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# CINRYZE

---

## Products Affected

- Cinryze

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Patient must have a confirmed diagnosis of HAE.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	The patient must have a history of more than one severe event per month. B vs D coverage determination.

# COLONY STIMULATING FACTORS

---

## Products Affected

- Zarxio
- Neulasta
- Neulasta Onpro

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# CORLANOR

---

## Products Affected

- Corlanor TABS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically accepted Indications.
<b>Off-Label Uses</b>	Chronic stable angina, in combination with beta-blocker therapy
<b>Exclusion Criteria</b>	1.) Blood pressure less than 90/50 mmHg. 2.) Sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present. 3.) Resting heart rate less than 60 bpm prior to treatment. 4.) Pacemaker dependence (heart rate maintained exclusively by the pacemaker).
<b>Required Medical Information</b>	Documentation of diagnosis, previous use of a beta-blocker, LVEF, sinus rhythm, resting HR, and blood pressure.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For use in chronic heart failure, the patient must have left ventricular ejection fraction less than or equal to 35%, normal sinus rhythm with resting heart rate greater than or equal to 70 beats per minute, and either be on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. For use in chronic angina, the patient must be using in combination with maximally tolerated doses of beta-blockers.

# CYSTARAN

---

## Products Affected

- Cystaran

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# DALFAMPRIDINE

---

## Products Affected

- Dalfampridine Er

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Dalfampridine is considered medically necessary for patients with multiple sclerosis with medical documentation of impaired walking ability.

# DEMSEER

---

## Products Affected

- Demser

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For initial therapy, approve if the patient has tried a selective alpha blocker (e.g., doxazosin, terazosin or prazosin) AND the patient has tried phenoxybenzamine (brand or generic). For continuation of therapy, approve if the patient is currently receiving Demser or has received Demser in the past.

# DERMATOLOGICAL RETINOIDS

---

## Products Affected

- Avita
- Tretinoin CREA
- Tretinoin GEL
- Tretinoin Microsphere GEL 0.1%
- Tretinoin Microsphere Pump GEL 0.1%

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Coverage is not provided for cosmetic use.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



# DERMATOLOGICAL WOUND CARE AGENTS

---

## Products Affected

- Regranex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# DIHYDROERGOTAMINE MESYLATE

---

## Products Affected

- Dihydroergotamine Mesylate SOLN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	N/A

# DRONABINOL

---

## Products Affected

- Dronabinol

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	B vs D coverage determination

# DUAVEE

---

## Products Affected

- Duavee

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For the prevention of postmenopausal osteoporosis, trial, failure, or intolerance of raloxifene is required prior to the use of Duavee.

# DUPIXENT

---

## **Products Affected**

- Dupixent

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Concurrent use with Xolair
<b>Required Medical Information</b>	Diagnosis, prescriber specialty, other medications tried and length of trials
<b>Age Restrictions</b>	asthma/AD-12 years of age and older. Chronic Rhinosinusitis-18 years of age and older
<b>Prescriber Restrictions</b>	Atopic Dermatitis-Prescribed by or in consultation with an allergist, immunologist or dermatologist, asthma-prescribed by or in consultation with an allergist, immunologist or pulmonologist
<b>Coverage Duration</b>	AD-Initial-16 weeks, Cont-1 year, asthma/Rhinosinusitis-initial-6 months, cont 1 year
<b>Other Criteria</b>	Atopic Dermatitis-Initial-meets both a and b: a.has used at least one medium, medium-high, high, and/or super-high-potency prescription topical corticosteroid OR has atopic dermatitis affecting ONLY the face, eyes/eyelids, skin folds, and/or genitalia and has tried tacrolimus ointment AND b.Inadequate efficacy was demonstrated with these previously tried topical prescription therapies, according to the prescribing physician.Continuation-Approve if the pt has responded to Dupixent therapy as determined by the prescribing physician. Asthma-Initial-approve if pt meets the following criteria (i, ii, and iii):i.Pt meets ONE of the following criteria (a or b):a)has a blood eosinophil level of greater than or equal to 150 cells per microliter within the previous 6 weeks or within 6 weeks prior to treatment with any anti-interleukin (IL) therapy or Xolair OR b)has oral corticosteroid-dependent asthma, per the prescriber AND ii.has received combination therapy with BOTH of the following (a and b): a)An inhaled corticosteroid (ICS) AND b)At least one additional asthma controller/maintenance medication (NOTE:An exception to the requirement for a trial of one additional asthma controller/maintenance medication can be made if the patient has already received anti-IL-5 therapy or Xolair used concomitantly with an ICS. Use of a combination inhaler containing both an ICS and a LABA would fulfil the requirement for both criteria a and b) AND iii.asthma is uncontrolled or was uncontrolled prior to starting any anti-IL therapy or Xolair as defined by ONE of the following (a, b, c, d or e): a)experienced two or more asthma

---

exacerbations requiring treatment with systemic corticosteroids in the previous year OR b)experienced one or more asthma exacerbation requiring hospitalization or an Emergency Department visit in the previous year OR c)has a forced expiratory volume in 1 second (FEV1) less than 80% predicted OR d)has an FEV1/forced vital capacity (FVC) less than 0.80 OR e)The patient's asthma worsens upon tapering of oral corticosteroid therapy. Continuation-Approve if meets the following criteria (i and ii): i.continues to receive therapy with one inhaled corticosteroid (ICS) or one ICS-containing combination inhaler AND ii.has responded to Dupixent therapy as determined by the prescribing physician. Chronic rhinosinusitis with Nasal Polyposis-Initial-pt is currently receiving therapy with an intranasal corticosteroid AND is experiencing significant rhinosinusitis symptoms such as nasal obstruction, rhinorrhea, or reduction/loss of smell according to the prescriber AND meets ONE of the following (a or b): a)has received treatment with a systemic corticosteroid within the previous 2 years or has a contraindication to systemic corticosteroid therapy OR b)has had prior surgery for nasal polyps. Continuation-approve if the pt continues to receive therapy with an intranasal corticosteroid AND pt has responded to Dupixent therapy as determined by the prescriber.

---

## ENDOCRINE AND METABOLIC AGENTS

---

### Products Affected

- Somavert

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The patient must have a diagnosis of acromegaly AND had inadequate response to surgery or radiation therapy or documentation these therapies are not appropriate for the patient.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



## ENZYME REPLACEMENT/MODIFIERS

---

### Products Affected

- Aldurazyme
- Elaprase
- Naglazyme

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# EPCLUSA

---

## Products Affected

- Epclusa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation from the medical record of diagnosis including genotype, current medication regimen, HCV-RNA levels, history of previous HCV therapies and presence/absence of cirrhosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 weeks, based on indication and established treatment guidelines
<b>Other Criteria</b>	N/A

# EPIDIOLEX

---

## Products Affected

- Epidiolex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of Lennox-Gastaut syndrome or Dravet syndrome
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ERIVEDGE

---

## Products Affected

- Erivedge

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of locally advanced or metastatic basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ERLEADA

---

## Products Affected

- Erleada

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Erleada is approved for use in combination with a gonadotropin-releasing hormone (GnRH) analog or in patients who have had a bilateral orchiectomy.

# EVOMELA

---

## Products Affected

- Evomela

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	B vs D coverage determination

# EXJADE

---

## Products Affected

- Exjade

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>Transfusion-related chronic iron overload, initial therapy - approve if the patient is receiving blood transfusions at regular intervals for various conditions (eg, thalassemia syndromes, myelodysplastic syndrome, chronic anemia, sickle cell disease) AND prior to starting therapy, the serum ferritin level is greater than 1,000 mcg/L.</p> <p>Non-transfusion-dependent thalassemia syndromes chronic iron overload, initial therapy - approve if prior to starting therapy the serum ferritin level is greater than 300 mcg/L.</p> <p>Continuation therapy - approve if the patient is benefiting from therapy as confirmed by the prescribing physician.</p>

# EYLEA

---

## Products Affected

- Eylea

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	Administered by or under the supervision of an ophthalmologist
<b>Coverage Duration</b>	3 years
<b>Other Criteria</b>	N/A



# FYCOMPA

---

## Products Affected

- Fycompa

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# GATTEX

---

## Products Affected

- Gattex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# HALAVEN

---

## Products Affected

- Halaven

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For metastatic breast cancer, documentation of prior treatment with an anthracycline and a taxane. For unresectable or metastatic liposarcoma, documentation of prior treatment with an anthracycline-containing regimen.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For metastatic breast cancer, patients must have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. B vs D coverage determination.

# HARVONI

---

## Products Affected

- Harvoni

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation from the medical record of diagnosis including genotype, current medication regimen, HCV-RNA levels, history of previous HCV therapies and presence/absence of cirrhosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 to 24 weeks based on indication and established treatment guidelines
<b>Other Criteria</b>	N/A

# HEMATOPOIETICS

---

## Products Affected

- Retacrit

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For initial treatment of anemia, documentation of Hemoglobin less than 10, transferrin saturation greater than 20%, and ferritin levels greater than 100 obtained over the last 3 months. For patients who do not meet iron store requirements to create red blood cells, approval can be given if evidence shows the patient has started supplemental iron. For continuation of therapy, approvals granted if Hemoglobin does not exceed 11 g/dL for chronic kidney disease anemia, 13g/dL for the indication of reduction of allogeneic red cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery, and 12g/dL for all other indications.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	B vs D coverage determination

# HETLIOZ

---

## Products Affected

- Hetlioz

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	A circadian rhythm longer than 24 hours has been confirmed by daily sleep logs and actigraphy for at least 14 days. Documentation that patient is totally blind and lacks light perception.
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# HORMONAL AGENTS, GONADOTROPINS

---

## Products Affected

- Chorionic Gonadotropin INJ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# HORMONAL AGENTS, SOMATOSTATIN ANALOGS

---

## Products Affected

- Octreotide Acetate
- Somatuline Depot

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



# HRM - BENZTROPINE

---

## Products Affected

- Benztropine Mesylate TABS

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed two (2) safer formulary alternatives if two are available or provided clinical rationale why two safer formulary alternatives are not appropriate for the patient. If only one (1) safer formulary alternative is available, then only that particular medication would need to be documented as tried and failed or clinical rationale provided as to why that one safer formulary alternative is not appropriate for the patient. For patients concurrently taking multiple anticholinergic medications, the physician has assessed the risk.
<b>Age Restrictions</b>	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Safer alternatives depend on indication. For Parkinsonism, safer alternatives are: Carbidopa/Levodopa, Pramipexole, Ropinirole, Bromocriptine, Amantadine, and Selegiline. For extrapyramidal symptoms, a safer alternative is: Amantadine.

# HRM - BUTALBITAL COMBINATIONS

---

## Products Affected

- Butalbital/acetaminophen/caffeine CAPS
- Butalbital/acetaminophen/caffeine TABS 325MG; 50MG; 40MG
- Esgic CAPS
- Zebutal CAPS 325MG; 50MG; 40MG

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed two (2) safer formulary alternatives or provided clinical rationale why two safer formulary alternatives are not appropriate for the patient.
<b>Age Restrictions</b>	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Safer alternatives are: naproxen sodium and ibuprofen.

# HRM - ESTROGENS

---

## Products Affected

- Dotti
- Estradiol ORAL TABS 0.5MG, 1MG, 2MG
- Estradiol PTTW
- Estradiol PTWK
- Fyavolv
- Norethindrone acetate-estradiol

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed two (2) safer formulary alternatives or provided clinical rationale why two safer formulary alternatives are not appropriate for the patient.
<b>Age Restrictions</b>	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: SSRIs, venlafaxine, and gabapentin. For Vaginal Symptoms of menopause, safer alternatives are: Premarin Cream, Yuvafem and vaginal estradiol tablets. For Bone Density, safer alternatives are: bisphosphonates, raloxifene, and Prolia.

## HRM - FIRST GENERATION ANTIHISTAMINES

---

### Products Affected

- Hydroxyzine Hcl

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed two (2) safer formulary alternatives or provided clinical rationale why two safer formulary alternatives are not appropriate for the patient.
<b>Age Restrictions</b>	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Safer alternatives to hydroxyzine hydrochloride depend on the indication. Anxiety: buspirone, paroxetine, venlafaxine, escitalopram, sertraline, duloxetine. For all other indications, no safer alternatives are required.

# HRM - MEGESTROL

---

## Products Affected

- Megestrol Acetate SUSP 40MG/ML
- Megestrol Acetate TABS

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects.
<b>Age Restrictions</b>	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For the treatment of cachexia/loss of appetite associated with AIDS (megestrol oral suspension only), the physician has documented that the patient has tried and failed dronabinol or provided clinical rationale as to why that safer formulary alternative is not appropriate for the patient. For all other indications, trial of dronabinol is not required.

# HRM - PERPHENAZINE/AMITRIPTYLINE

---

## Products Affected

- Perphenazine/amitriptyline

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed two (2) safer formulary alternatives or provided clinical rationale why two safer formulary alternatives are not appropriate for the patient. For patients concurrently taking multiple anticholinergic medications, the physician has assessed the risk.
<b>Age Restrictions</b>	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion.

# HRM - PLATELET MODIFYING AGENTS

---

## Products Affected

- Dipyridamole TABS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed two (2) safer formulary alternatives or provided clinical rationale why two safer formulary alternatives are not appropriate for the patient.
<b>Age Restrictions</b>	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Safer alternatives are: Clopidogrel, Warfarin, Jantoven, and aspirin/dipyridamole .

# HRM - PROMETHAZINE

---

## **Products Affected**

- Promethazine Hcl SYRP
- Promethazine Hcl TABS 12.5MG
- Promethazine Hcl Plain
- Promethazine Hydrochloride TABS  
25MG, 50MG



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed two safer formulary alternatives if available or provided clinical rationale why the safer formulary alternative is not appropriate for the patient. If only one (1) safer formulary alternative is available, then only that particular medication would need to be documented as tried and failed or clinical rationale provided as to why that one safer formulary alternative is not appropriate for the patient. For patients concurrently taking other anticholinergic medications, the physician has assessed the risk.
<b>Age Restrictions</b>	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For postoperative nausea and vomiting, the safer alternative is ondansetron. For perennial and seasonal allergic rhinitis, safer alternatives are: levocetirizine and desloratadine. For any other indications, trial of a formulary alternative is not required.

# HRM - SKELETAL MUSCLE RELAXANTS

---

## Products Affected

- Cyclobenzaprine Hydrochloride  
TABS 10MG, 5MG
- Methocarbamol TABS

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects. For patients concurrently taking multiple anticholinergic medications, the physician has assessed the risk.
<b>Age Restrictions</b>	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

## HRM - TRICYCLIC ANTIDEPRESSANTS

---

### Products Affected

- Amitriptyline Hcl TABS 100MG, 150MG, 25MG, 75MG
- Amitriptyline Hydrochloride TABS 10MG, 50MG
- Clomipramine Hcl CAPS
- Doxepin Hcl CAPS 100MG, 10MG, 150MG, 50MG, 75MG
- Doxepin Hcl CONC
- Doxepin Hydrochloride CAPS 25MG
- Imipramine Hcl TABS 25MG, 50MG
- Imipramine Hydrochloride TABS 10MG
- Trimipramine Maleate CAPS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects AND the physician has documented that the patient has tried and failed two (2) safer formulary alternatives or provided clinical rationale why two safer formulary alternatives are not appropriate for the patient. For patients concurrently taking multiple anticholinergic medications, the physician has assessed the risk.
<b>Age Restrictions</b>	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Escitalopram, Fluvoxamine, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, Rizatriptan and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin. If using requested medication for a medically-accepted indication not listed above, then no trial of alternatives is required.

# HYDROXYPROGESTERONE

---

## Products Affected

- Hydroxyprogesterone Caproate INJ  
1.25GM/5ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	B vs D coverage determination

# ICATIBANT

---

## Products Affected

- Icatibant Acetate

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Patient must have a confirmed diagnosis of HAE.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Icatibant is considered medically necessary for the treatment of acute attacks of hereditary angioedema (HAE) in patients who have tried and failed Ruconest.

# IDIOPATHIC PULMONARY FIBROSIS

---

## Products Affected

- Esbriet
- Ofev

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	For the diagnosis of IPF, other known causes of interstitial lung disease e.g., domestic and occupational environmental exposures, connective tissue disease, and drug toxicity.
<b>Required Medical Information</b>	Diagnosis of IPF confirmed by 1.) in patients without surgical lung biopsy: Usual interstitial pneumonia (UIP) pattern on high resolution computed tomography (HRCT) is indicative of IPF or 2.) in patients with surgical lung biopsy: The biopsy pattern is diagnostic of IPF or the combination of HRCT and biopsy pattern is indicative of IPF. For use of Ofev in systemic sclerosis-associated interstitial lung disease (SSc-ILD) no further documentation is required.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Esbriet and Ofev will each be used as monotherapy.

# IMMUNE STIMULANTS

---

## Products Affected

- Adagen

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



# IMMUNE SUPPRESSANTS

---

## **Products Affected**

- Enbrel
- Enbrel Mini
- Enbrel Sureclick
- Humira
- Humira Pediatric Crohns Disease Starter Pack
- Humira Pen
- Humira Pen-cd/uc/hs Starter
- Humira Pen-ps/uv Starter
- Skyrizi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis and past medication history.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>1.) Use of Humira or Enbrel is considered medically necessary for the treatment of Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least one alternative disease modifying antirheumatic drugs (DMARDs). A previous trial of a biologic also counts as a trial.</p> <p>2.) Use of Humira or Enbrel is considered medically necessary for the treatment of Juvenile Rheumatoid Arthritis in patients that have tried and failed at least one other agent (e.g. MTX, sulfasalazine, leflunomide, or DMARD) or will be starting on a adalimumab concurrently with MTX, sulfasalazine, or leflunomide. Approve without trying another agent if patient has absolute contraindication to MTX, sulfasalazine, or leflunomide or if patient has aggressive disease. A previous trial of a biologic also counts as a trial.</p> <p>3.) Use of Humira or Enbrel is considered medically necessary for the treatment of Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal anti-inflammatory drug (NSAID), corticosteroid, OR sulfasalazine. A previous trial of a biologic also counts as a trial.</p> <p>4.) Use of Humira, Enbrel, or Sykrizi is considered medically necessary for the treatment of Plaque Psoriasis in patients that have: a.) moderate to severe chronic disease, b.) minimum body surface area (BSA) involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, AND c.) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene) OR one systemic agent (e.g. MTX, cyclosporine, etc.) A previous trial of a biologic also counts as a trial.</p>

- 
- 5.) Use of Humira or Enbrel is considered medically necessary for the treatment of Psoriatic Arthritis in patients with active disease.
- 6.) Use of Humira is considered medically necessary for the treatment of moderate to severe Crohn's Disease in patients that have tried and failed at least 1 of the following: immunomodulators, corticosteroids, or aminosalicylates. A previous trial of a biologic also counts as a trial.
- 7.) Use of Humira is considered medically necessary for the treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 1 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine, cyclosporine, tacrolimus. A previous trial of a biologic also counts as a trial.
- 8.) Use of Humira is considered medically necessary for the treatment of hidradenitis suppurativa and uveitis.
-

## IMMUNE SUPPRESSANTS - RINVOQ

---

### Products Affected

- Rinvoq

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis and past medication history.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	1.) Rinvoq is considered medically necessary for the treatment of Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least one alternative disease modifying antirheumatic drugs (DMARDs). A previous trial of a biologic also counts as a trial.

## IMMUNE SUPPRESSANTS - STELARA

---

### Products Affected

- Stelara INJ 45MG/0.5ML, 90MG/ML

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	Documentation of diagnosis and past medication history.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	<p>1.) Stelara is considered medically necessary for the treatment of Plaque Psoriasis in patients that have: a.) moderate to severe chronic disease, b.) minimum body surface area (BSA) involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, AND c.) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene) OR one systemic agent (e.g. MTX, cyclosporine, etc.). A previous trial of a biologic also counts as a trial.</p> <p>2.) Stelara is considered medically necessary for the treatment of Psoriatic Arthritis in patients with active disease.</p> <p>3.) Stelara is considered medically necessary for the treatment of moderate to severe Crohn's Disease in patients that have tried and failed at least 1 of the following: immunomodulators, corticosteroids, or aminosalicylates. A previous trial of a biologic also counts as a trial.</p> <p>4.) Stelara is considered medically necessary for the treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 1 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine, cyclosporine, tacrolimus. A previous trial of a biologic also counts as a trial.</p>



## IMMUNE SUPPRESSANTS - TRANSPLANT RELATED

---

### Products Affected

- Azathioprine INJ
- Azathioprine TABS
- Cyclosporine CAPS
- Cyclosporine INJ
- Cyclosporine Modified
- Gengraf CAPS 100MG, 25MG
- Gengraf SOLN
- Mycophenolate Mofetil
- Mycophenolic Acid Dr
- Prograf PACK
- Rapamune SOLN
- Sandimmune SOLN
- Sirolimus SOLN
- Sirolimus TABS
- Tacrolimus CAPS
- Zortress

PA Criteria	Criteria Details
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	B vs D coverage determination

## IMMUNE SUPPRESSANTS - XELJANZ

---

### Products Affected

- Xeljanz
- Xeljanz Xr

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis and past medication history.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>1.) Xeljanz is considered medically necessary for the treatment of Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least one alternative disease modifying antirheumatic drugs (DMARDs). A previous trial of a biologic also counts as a trial. For Rheumatoid Arthritis, dosing 10mg twice a day will not be approved in patients with at least one cardiovascular risk factor.</p> <p>2.) Xeljanz is considered medically necessary for the treatment of Psoriatic Arthritis in patients with active disease. For Psoriatic Arthritis, dosing 10mg twice a day will not be approved in patients with at least one cardiovascular risk factor.</p> <p>3.) Xeljanz is considered medically necessary for the treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 1 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine, cyclosporine, tacrolimus. A previous trial of a biologic also counts as a trial.</p>



# IMMUNOMODULATORS

---

## Products Affected

- Betaseron
- Gilenya CAPS 0.5MG
- Glatiramer Acetate
- Tecfidera
- Tecfidera Starter Pack

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically accepted Indications.
<b>Off-Label Uses</b>	Multiple Sclerosis, Clinically Isolated Syndrome (Betaseron)
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of a relapsing form of multiple sclerosis (MS) (e.g., relapsing-remitting MS, progressive-relapsing MS, or secondary progressive MS with relapses), or diagnosis of Clinically Isolated Syndrome.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Requests for Clinically Isolated Syndrome will be approved for Betaseron only.

# INFLIXIMAB

---

## Products Affected

- Renflexis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis and past medication history.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>1.) Use of Renflexis is considered medically necessary for the treatment of Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least one alternative disease modifying antirheumatic drugs (DMARDs).</p> <p>2.) Use of Renflexis is considered medically necessary for the treatment of Juvenile Rheumatoid Arthritis in patients that have tried and failed at least one other agent (e.g. MTX, sulfasalazine, leflunomide, or DMARD). Approve without trying another agent if patient has absolute contraindication to MTX, sulfasalazine, or leflunomide or if patient has aggressive disease.</p> <p>3.) Use of Renflexis is considered medically necessary for the treatment of Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal anti-inflammatory drug (NSAID), corticosteroid, OR sulfasalazine.</p> <p>4.) Use of Renflexis is considered medically necessary for the treatment of Plaque Psoriasis in patients that have: a.) moderate to severe chronic disease, b.) minimum body surface area (BSA) involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, AND c.) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene) OR one systemic agent (e.g. MTX, cyclosporine, etc.)</p> <p>5.) Use of Renflexis is considered medically necessary for the treatment of Psoriatic Arthritis in patients with active disease.</p> <p>6.) Use of Renflexis is considered medically necessary for the treatment of moderate to severe Crohn's Disease in patients that have tried and</p>

---

failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates

7.) Use of Renflexis is considered medically necessary for the treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine.

8.) Use of Renflexis is considered medically necessary for the treatment of fistulizing Crohn's disease.

B vs D coverage determination required for Renflexis.

---

# INSULIN-LIKE GROWTH FACTOR

---

## Products Affected

- Increlex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis. Documentation of lab data reflecting height standard deviation score, basal IGF-1 score, and growth hormone level.
<b>Age Restrictions</b>	Patients 2 years of age or older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Height standard deviation score must be less than or equal to -3.0 AND the basal IGF-1 score must be below the lower limits of normal for the reporting lab AND the patient must have a normal or elevated growth hormone level (excluding patients with growth hormone gene deletion) AND epiphyses must be confirmed as open in patients greater than or equal to 10 years of age.

# ISTODAX

---

## Products Affected

- Istodax (overfill)
- Romidepsin

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis and past medication history.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Use of Istodax is considered medically necessary for the treatment of cutaneous T-cell lymphoma in patients that have tried and failed at least 1 prior therapy. B vs D coverage determination.

# KALYDECO

---

## Products Affected

- Kalydeco

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Patients with cystic fibrosis (CF) who are homozygous for the F508del mutation in the CFTR gene. Kalydeco will not be used in combination with Orkambi or Symdeko
<b>Required Medical Information</b>	CF mutation test documenting patient has one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# KORLYM

---

## Products Affected

- Korlym

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



# KUVAN

---

## Products Affected

- Kuvan

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis, Phe concentration
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Initial Approval: 2 months. Continuation of therapy: 12 months.
<b>Other Criteria</b>	For continuation of therapy: the patient must have responded to a therapeutic trial of Kuvan. Response is defined as a 20% or greater reduction in blood phenylalanine level from baseline.

# LIDOCAINE PATCH

---

## Products Affected

- Lidocaine PTCH

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For the FDA-labeled indication of post-herpetic neuralgia, no additional criteria are required to be met. For diabetic neuropathic pain: the patient must have previous use and inadequate response or intolerance to any ONE medication that is FDA-labeled for diabetic peripheral neuropathy, including duloxetine and Lyrica. For cancer related neuropathic pain (including treatment-related neuropathy), no additional criteria are required to be met.

# LUMIZYME

---

## Products Affected

- Lumizyme

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	B vs D coverage determination

# MAVYRET

---

## Products Affected

- Mavyret

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation from the medical record of diagnosis including genotype, current medication regimen, HCV-RNA levels, history of previous HCV therapies and presence/absence of cirrhosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	8-16 weeks, based on indication and established treatment guidelines
<b>Other Criteria</b>	N/A

## METABOLIC BONE DISEASE AGENTS

---

### Products Affected

- Forteo INJ 600MCG/2.4ML
- Tymlos

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Cumulative use of parathyroid hormone analogs for more than 2 years during a patient's lifetime
<b>Required Medical Information</b>	Diagnosis of osteoporosis based on DEXA (T-score less than or equal to -2.5) or based on presence of documented fragility fracture.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	2 years from initiation of therapy
<b>Other Criteria</b>	Member has tried and/or failed a bisphosphonate or SERM OR the member has documented intolerance, contraindication, or hypersensitivity to other osteoporosis therapies. For patients with a T-score less than or equal to -3.5, failure of bisphosphonates or SERMs are not required.

# MOLECULAR TARGET INHIBITORS

---

## Products Affected

- Afinitor
- Afinitor Disperz
- Alecensa
- Alunbrig
- Balversa
- Bosulif
- Braftovi CAPS 75MG
- Cabometyx
- Calquence
- Caprelsa
- Cometriq
- Copiktra
- Cotellic
- Daurismo
- Erlotinib Hydrochloride
- Everolimus (antineoplastic)
- Farydak
- Gilotrif
- Ibrance
- Iclusig
- Idhifa
- Imatinib Mesylate
- Imbruvica
- Inlyta
- Inrebic
- Iressa
- Jakafi
- Kisqali
- Kisqali Femara 200 Dose
- Kisqali Femara 400 Dose
- Kisqali Femara 600 Dose
- Lenvima 10 Mg Daily Dose
- Lenvima 12mg Daily Dose
- Lenvima 14 Mg Daily Dose
- Lenvima 18 Mg Daily Dose
- Lenvima 20 Mg Daily Dose
- Lenvima 24 Mg Daily Dose
- Lenvima 4 Mg Daily Dose
- Lenvima 8 Mg Daily Dose
- Lonsurf
- Lorbrena
- Lynparza TABS

- Mekinist
- Mektovi
- Nerlynx
- Nexavar
- Ninlaro
- Piqray 200mg Daily Dose
- Piqray 250mg Daily Dose
- Piqray 300mg Daily Dose
- Pomalyst
- Rubraca
- Rydapt
- Sprycel
- Stivarga
- Sutent
- Synribo
- Tafinlar
- Tagrisso
- Talzenna
- Tassigna
- Tibsovo
- Tykerb
- Venclexta
- Venclexta Starting Pack
- Verzenio
- Vizimpro
- Votrient
- Xalkori
- Xospata
- Xpovio 100 Mg Once Weekly
- Xpovio 60 Mg Once Weekly
- Xpovio 80 Mg Once Weekly
- Xpovio 80 Mg Twice Weekly
- Xtandi
- Zejula
- Zelboraf
- Zydelig
- Zykadia
- Zytiga



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# MONOCLONAL ANTIBODIES

---

## Products Affected

- Xolair

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For the diagnosis of asthma: Laboratory data reflecting IgE levels greater than 30 IU/mL, medical history documenting previous trial and inadequate response to inhaled corticosteroids and a second controller such as a long-acting beta-agonist or a leukotriene receptor antagonist. For the diagnosis of chronic idiopathic urticaria (CIU): Documentation that the patient has remained symptomatic despite at least 4 weeks of a second generation H1 antihistamine (such as but not limited to levoceterizine or desloratadine) therapy at twice the recommended dosing.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Xolair will not be used concomitantly with Cinqair, Dupixent, Fasenna or Nucala

# NATPARA

---

## Products Affected

- Natpara

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Chronic hypoparathyroidism, initial therapy - approve if before starting Natpara, serum calcium concentration is greater than 7.5 mg/dL and 25-hydroxyvitamin D stores are sufficient per the prescribing physician. Chronic hypoparathyroidism, continuing therapy - approve if during Natpara therapy, the patient's 25-hydroxyvitamin D stores are sufficient per the prescribing physician AND the patient is responding to Natapara therapy, as determined by the prescriber.

# NAYZILAM

---

## Products Affected

- Nayzilam

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Use will be for treatment of intermittent, stereotypic episodes of frequent seizure activity (for example, seizure clusters, acute repetitive seizures) that are distinct from the individual's usual seizure pattern.
<b>Age Restrictions</b>	12 years of age and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Individual is currently receiving maintenance antiepileptic medication.

# NMDA RECEPTOR ANTAGONIST

---

## Products Affected

- Memantine Hcl Titration Pak
- Memantine Hydrochloride SOLN
- Memantine Hydrochloride TABS
- Memantine Hydrochloride Er

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	Automatic approval if member is greater than 26 years of age. Prior Authorization is required for age 26 or younger.
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# NON-AMPHETAMINE CENTRAL NERVOUS SYSTEM AGENTS

---

## Products Affected

- Armodafinil

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis and sleep study for the diagnosis of sleep apnea or narcolepsy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# NORTHERA

---

## Products Affected

- Northera

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Northera will be used for patients with neurogenic orthostatic hypotension associated with one of the following diagnoses: 1.) Primary autonomic failure due to Parkinson's disease, multiple system atrophy, or pure autonomic failure, OR 2.) Dopamine beta hydroxylase deficiency, OR 3.) Non-diabetic autonomic neuropathy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	The patient must have failure, contraindication or intolerance to fludrocortisone acetate or midodrine.

# NUEDEXTA

---

## Products Affected

- Nuedexta

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



# NULOJIX

---

## Products Affected

- Nulojix

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of Epstein-Barr virus serology and current medication regimen.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Documentation of use in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. B vs D coverage determination.

# NUPLAZID

---

## Products Affected

- Nuplazid

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For the treatment of Parkinson's disease psychosis: The patient has experienced hallucinations or delusions associated with Parkinson's disease psychosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# Ocaliva

## Products Affected

- Ocaliva

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Prescriber specialty, lab values, prior medications used for diagnosis and length of trials
<b>Age Restrictions</b>	18 years and older (initial and continuation therapy)
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician (initial and continuation therapy)
<b>Coverage Duration</b>	6 months initial, 3 years cont.
<b>Other Criteria</b>	Initial treatment of PBC-Patient must meet both 1 and 2-1. Patient has a diagnosis of PBC as defined by TWO of the following:a)Alkaline phosphatase (ALP) elevated above the upper limit of normal as defined by normal laboratory reference values b)Positive anti-mitochondrial antibodies (AMAs) c)Histologic evidence of primary biliary cholangitis (PBC) from a liver biopsy 2. Patient meets ONE of the following: a) Patient has been receiving ursodiol therapy for greater than or equal to 1 year and has had an inadequate response. b) Patient is unable to tolerate ursodiol therapy. Cont tx - approve if the patient has responded to Ocaliva therapy as determined by the prescribing physician (e.g., improved biochemical markers of PBC (e.g., alkaline phosphatase [ALP], bilirubin, gamma-glutamyl transpeptidase [GGT], aspartate aminotransferase [AST], alanine aminotransferase [ALT] levels)).

# OCREVUS

---

## Products Affected

- Ocrevus

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	Prescribed by, or in consultation with, a physician who specializes in the treatment of MS and/or a neurologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	N/A

# ODOMZO

---

## Products Affected

- Odomzo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	For the treatment of Locally Advanced Basal Cell Carcinoma: the cancer has recurred following surgery or radiation therapy OR the patient is not a candidate for surgery or radiation therapy.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ORENCIA

---

## Products Affected

- Orenzia INJ 125MG/ML, 50MG/0.4ML, 87.5MG/0.7ML
- Orenzia Clickject

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis and past medication history.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>1.) Orenzia SC is considered medically necessary for the treatment of Rheumatoid Arthritis in patients that have a.) tried and failed methotrexate OR an alternative disease modifying antirheumatic drugs (DMARDs) AND b.) tried and failed Enbrel or Humira.</p> <p>2.) Use of Orenzia SC is considered medically necessary for the treatment of Juvenile Rheumatoid Arthritis in patients that have a.) tried and failed at least 1 DMARD AND b.) tried and failed Enbrel or Humira.</p> <p>3.) Use of Orenzia SC is considered medically necessary for the treatment of: Psoriatic Arthritis in patients with active disease that have tried and failed Enbrel or Humira.</p>

# ORKAMBI

---

## Products Affected

- Orkambi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Combination use with Symdeko
<b>Required Medical Information</b>	CF mutation test documenting the patient is homozygous for the F508del mutation in the CFTR gene.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# PADCEV

---

## Products Affected

- Padcev

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved indications not otherwise excluded from Part D.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis, prior therapies
<b>Age Restrictions</b>	18 years and older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Urothelial carcinoma-approve if the patient has locally advanced or metastatic disease, has previously received a programmed death receptor-1 or programmed death-ligand 1 inhibitor and has previously received platinum containing chemotherapy. B vs D coverage determination



## PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS

---

### Products Affected

- Daliresp

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For initial therapy: trial and failure, contraindication, or intolerance to two formulary inhaled COPD agents is required. For continuation of therapy, approve if patient has already been started on Daliresp.

# PITUITARY HORMONES

---

## Products Affected

- Genotropin
- Genotropin Miniquick
- Leuprolide Acetate INJ
- Lupron Depot (1-month)
- Lupron Depot (3-month)
- Lupron Depot (4-month)
- Lupron Depot (6-month)
- Lupron Depot-ped (1-month)
- Lupron Depot-ped (3-month)
- Nubeqa
- Synarel
- Trelstar Mixject
- Triptodur

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# PROMACTA

---

## Products Affected

- Promacta

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Use of Promacta for the treatment of thrombocytopenia is considered medically necessary in: a.) patients with chronic hepatitis C, or b.) patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) that have failed corticosteroid OR intravenous immune globulin (IVIG) therapy OR have had an insufficient response to a splenectomy, or c.) severe aplastic anemia with documentation of inadequate response to previous immunosuppressive therapy (e.g. Atgam, Thymoglobulin, cyclosporine) or being used in combination with standard immunosuppressive therapy.

# PURIXAN

---

## Products Affected

- Purixan

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Documentation of trial, contraindication, or failure to mercaptopurine tablets.

# QUNINIE SULFATE

---

## Products Affected

- Quinine Sulfate CAPS 324MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically accepted Indications.
<b>Off-Label Uses</b>	Babesiosis, uncomplicated Plasmodium vivax malaria.
<b>Exclusion Criteria</b>	Excluded if used for treatment or prevention of nocturnal leg cramps.
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	N/A

# RELISTOR

---

## Products Affected

- Relistor INJ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis and past medication history.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Use of Relistor is considered medically necessary for the treatment of opioid-induced constipation in patients with advanced illnesses who are receiving palliative care AND have tried and failed laxative therapy with lactulose or polyethylene glycol. Relistor is also considered medically necessary for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain who have tried and failed laxative therapy with lactulose or polyethylene glycol AND Amitiza.

# REPATHA

---

## **Products Affected**

- Repatha
- Repatha Pushtronex System
- Repatha Sureclick

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Diagnosis of one of the following: Clinical atherosclerotic cardiovascular disease (ASCVD) OR Primary Hyperlipidemia (including Heterozygous familial hypercholesterolemia (HeFH)) OR Homozygous Familial Hypercholesterolemia (HoFH) (confirmed by either: Genetic testing or History of untreated low-density lipoprotein cholesterol (LDL-C) greater than 500mg/dl or treated LDL greater than 300mg/dl with either: presence of xanthomas before the age of 10 years or evidence of heterozygous familial hypercholesterolemia in both parents.)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Initial:6 mo. Cont. of therapy: 12 months
<b>Other Criteria</b>	For ASCVD or Primary Hyperlipidemia (including HeFH): Patient is on high-intensity statin therapy or maximally tolerated statin therapy, is not at LDL-C level goal (LDL-C greater than 70 mg/dL) and will be continued on high intensity or maximally tolerated statin therapy while on the PCSK9-inhibitor. Patients intolerant to statins as demonstrated by experiencing statin-associated rhabdomyolysis to one statin OR has tried 2 statins (any combination of high or moderate intensity statins) and has experienced skeletal–muscle related symptoms on both agents, no concurrent statin use required. For HoFH: Patient is on high-intensity or maximally tolerated lipid lowering therapy (such as statins and/or ezetimibe), is not at LDL-C level goal (LDL-C greater than 70 mg/dL), and will be continued on high intensity or maximally tolerated lipid lowering therapy while on Repatha. For patients with HoFH who are intolerant to statins, no concurrent statin use required. Continuation of therapy requires documented evidence of clinical benefit response.



# REVLIMID

---

## Products Affected

- Revlimid

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# ROZLYTREK

---

## Products Affected

- Rozlytrek

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	1. Documentation of metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. OR 2. Documentation of a solid tumors that has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. Patient is metastatic or where surgical resection is likely to result in severe morbidity. Patient has no satisfactory alternative treatments or has progressed following treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# RUCONEST

---

## Products Affected

- Ruconest

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Patient must have a confirmed diagnosis of HAE.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# SAMSCA

---

## Products Affected

- Samsca

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Maximum of 30 days for each course of treatment (initial or retreatment)
<b>Other Criteria</b>	Samsca is considered medically necessary for the treatment of patients with significant hypervolemic and euvolemic hyponatremia (serum sodium less than 125 mEq/L) or symptomatic hyponatremia.

# SIGNIFOR

---

## Products Affected

- Signifor

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# SIRTURO

---

## Products Affected

- Sirturo

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation from the medical record required indicating the patient has multi-drug resistant tuberculosis resistant to isoniazid and rifampin.
<b>Age Restrictions</b>	18 years of age and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Use of Sirturo for the treatment of multi-drug resistant tuberculosis is considered medically necessary in patients with multi-drug resistant tuberculosis in combination with at least 3 other agents.

# SODIUM PHENYL BUTYRATE

---

## Products Affected

- Sodium Phenylbutyrate POWD  
3GM/TSP
- Sodium Phenylbutyrate TABS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# SYLATRON

---

## Products Affected

- Sylatron

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A



# SYMPAZAN

---

## Products Affected

- Sympazan

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Failure, contraindication, or intolerance to clobazam tablets and oral solution before Sympazan is authorized.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# SYNAGIS

---

## Products Affected

- Synagis INJ 100MG/ML,  
50MG/0.5ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	24 months or younger
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	N/A

# TARGRETIN (TOPICAL)

---

## Products Affected

- Targretin GEL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# TETRABENAZINE

---

## Products Affected

- Tetrabenazine

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis of chorea associated with Huntington's Disease. CYP 2D6 genotype must be provided for doses greater than 50mg/day.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# THALIDOMIDE (THALOMID)

---

## Products Affected

- Thalomid

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# THIOTEPA

---

## Products Affected

- Thiotepa INJ 15MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	B vs D coverage determination

# TRANSMUCOSAL FENTANYL CITRATE

---

## Products Affected

- Fentanyl Citrate Oral Transmucosal

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation from the medical record of diagnosis.
<b>Age Restrictions</b>	16 years of age and older for fentanyl citrate (lozenge/troche)
<b>Prescriber Restrictions</b>	Enrollment in the Transmucosal Immediate-Release Fentanyl (TIRF) REMS Access program.
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Transmucosal fentanyl products will only be covered with documentation of breakthrough cancer pain. The patient must be currently receiving and be tolerant to opioid therapy for persistent cancer pain. The patient must be enrolled in the TIRF REMS Access program.

# TYSABRI

---

## Products Affected

- Tysabri

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>Treatment of relapsing forms of multiple sclerosis (MS) when EITHER of the following criteria is met: 1.) history of beneficial clinical response to Tysabri (natalizumab) for MS or 2.) failure, contraindication or intolerance to one formulary alternative (eg. Betaseron, Gilenya, glatiramer).</p> <p>Treatment of moderately to severely active Crohn’s disease (CD) when EITHER of the following criteria is met: 1.) history of beneficial clinical response to Tysabri (natalizumab) for CD or 2.) failure or intolerance to Humira.</p>



# UPTRAVI

---

## Products Affected

- Uptravi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of pulmonary arterial hypertension.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	Patient new to Uptravi therapy must meet a) OR b): a) tried TWO or is currently taking TWO oral therapies for PAH (either alone or in combination) each for 30 days, unless patient has experienced treatment failure, intolerance, or oral therapy is contraindicated: PDE5 inhibitor (eg, sildenafil, Revatio), endothelin receptor antagonist (ERA) [eg, Tracleer, Letairis or Opsumit], or Adempas, OR b) receiving or has received in the past one prostacyclin therapy for PAH (eg, Orenitram, Ventavis, or epoprostenol injection).

# VALCHLOR GEL

---

## Products Affected

- Valchlor

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of diagnosis and past medical history.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Valchlor Topical Gel is considered medically necessary for the treatment of patients with Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma who have received prior skin-directed therapy.

# VASODILATORS

---

## Products Affected

- Adempas
- Bosentan
- Ambrisentan
- Letairis
- Sildenafil Citrate TABS 20MG
- Tracleer TBSO

PA Criteria	Criteria Details
<b>Indications</b>	All FDA-approved Indications, Some Medically accepted Indications.
<b>Off-Label Uses</b>	Secondary Reynaud's phenomenon (sildenafil 20mg), Rebound pulmonary hypertension caused by nitric oxide withdrawal (sildenafil 20mg), Persistent pulmonary hypertension of the newborn (sildenafil 20mg), Eisenmenger's syndrome with WHO functional class III (bosentan, Tracleer).
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of pulmonary arterial hypertension. Adempas will also be approved for chronic thromboembolic pulmonary hypertension.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Sildenafil 20mg will also be considered medically necessary for Secondary Reynaud's phenomenon, rebound pulmonary hypertension caused by nitric oxide withdrawal, or persistent pulmonary hypertension of the newborn. Tracleer and bosentan will also be considered medically necessary for Eisenmenger's syndrome with WHO functional class III.

# VENTAVIS

---

## Products Affected

- Ventavis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	B vs D coverage determination

# VIGABATRIN

---

## Products Affected

- Vigabatrin
- Vigadrone

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation from the medical record of diagnosis and past medication history.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Vigabatrin is considered medically necessary in patients that have failed to receive a clinically appropriate response from optimal doses and administration of at least two of the following: phenytoin, divalproex, lamotrigine, and levetiracetam. For the indication of Infantile Spasms, failure of another drug(s) is not required.

# VITRAKVI

---

## Products Affected

- Vitrakvi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of a solid tumors that has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. Patient is metastatic or where surgical resection is likely to result in severe morbidity. Patient has no satisfactory alternative treatments or has progressed following treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# VIVITROL

---

## Products Affected

- Vivitrol

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Documentation of a solid tumors that has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. Patient is metastatic or where surgical resection is likely to result in severe morbidity. Patient has no satisfactory alternative treatments or has progressed following treatment.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# VOSEVI

---

## Products Affected

- Vosevi

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	Treatment naive patients (exception: treatment-naïve patients with genotype 3 with compensated cirrhosis and a Y93H mutation will be approved)
<b>Required Medical Information</b>	Documentation from the medical record of diagnosis including genotype, current medication regimen, HCV-RNA levels, history of previous HCV therapies and presence/absence of cirrhosis.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 weeks, based on indication and established treatment guidelines
<b>Other Criteria</b>	N/A



# XATMEP

---

## Products Affected

- Xatmep

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# XGEVA

---

## Products Affected

- Xgeva

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For initial therapy in the treatment of hypercalcemia of malignancy: trial and failure, contraindication, or intolerance to one intravenous bisphosphonate (e.g. pamidronate, zoledronic acid) is required. For continuation of therapy in the treatment of hypercalcemia of malignancy, approve if patient has already been started on Xgeva. For other medically accepted indication, no trial of alternatives is required.

# XIFAXAN

---

## Products Affected

- Xifaxan TABS 550MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

# XIAFLEX

---

## Products Affected

- Xiaflex

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	Xiaflex is authorized for the treatment of a symptomatic Dupuytren's contracture in adults when there is both a palpable cord and a functional impairment as manifested by a metacarpophalangeal (MCP) joint or proximal interphalangeal (PIP) joint contracture of 20 degrees or greater.
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	B vs D coverage determination

# XYREM

---

## Products Affected

- Xyrem

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off-Label Uses</b>	N/A
<b>Exclusion Criteria</b>	The patient must not be taking any sedative hypnotic agents or other CNS depressants.
<b>Required Medical Information</b>	Documentation of diagnosis, sleep study
<b>Age Restrictions</b>	7 years of age and older
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For the initial treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy: trial and failure, contraindication, or intolerance to one CNS stimulant (e.g., methylphenidate, dexamethylphenidate, dextroamphetamine) or armodafinil is required. For continuation of therapy in the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy, approve if patient has already been started on Xyrem. For other medically accepted indication, no trial of alternatives is required.

# ZTLIDO

---

## Products Affected

- Ztlido

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications, Some Medically accepted Indications.
<b>Off-Label Uses</b>	Diabetic neuropathic pain, cancer related neuropathy
<b>Exclusion Criteria</b>	N/A
<b>Required Medical Information</b>	N/A
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	N/A

## **PART B VERSUS PART D**

---

## Products Affected

- Acetylcysteine SOLN
- Acyclovir Sodium INJ 50MG/ML
- Albuterol Sulfate NEBU
- Aminosyn INJ 148MEQ/L;  
1280MG/100ML; 980MG/100ML;  
1280MG/100ML; 300MG/100ML;  
720MG/100ML; 940MG/100ML;  
720MG/100ML; 400MG/100ML;  
440MG/100ML; 860MG/100ML;  
420MG/100ML; 520MG/100ML;  
160MG/100ML; 44MG/100ML;  
800MG/100ML, 90MEQ/L;  
1100MG/100ML; 850MG/100ML;  
35MEQ/L; 1100MG/100ML;  
260MG/100ML; 620MG/100ML;  
810MG/100ML; 624MG/100ML;  
340MG/100ML; 380MG/100ML;  
750MG/100ML; 370MG/100ML;  
460MG/100ML; 150MG/100ML;  
44MG/100ML; 680MG/100ML
- Aminosyn II INJ 107.6MEQ/L;  
1490MG/100ML; 1527MG/100ML;  
1050MG/100ML; 1107MG/100ML;  
750MG/100ML; 450MG/100ML;  
990MG/100ML; 1500MG/100ML;  
1575MG/100ML; 258MG/100ML;  
447MG/100ML; 1083MG/100ML;  
795MG/100ML; 50MEQ/L;  
600MG/100ML; 300MG/100ML;  
405MG/100ML; 750MG/100ML,  
71.8MEQ/L; 993MG/100ML;  
1018MG/100ML; 700MG/100ML;  
738MG/100ML; 500MG/100ML;  
300MG/100ML; 660MG/100ML;  
1000MG/100ML; 1050MG/100ML;  
172MG/100ML; 298MG/100ML;  
722MG/100ML; 530MG/100ML;  
38MEQ/L; 400MG/100ML;  
200MG/100ML; 270MG/100ML;  
500MG/100ML



- Aminosyn M INJ 65MEQ/L;  
448MG/100ML; 343MG/100ML;  
40MEQ/L; 448MG/100ML;  
105MG/100ML; 252MG/100ML;  
329MG/100ML; 252MG/100ML;  
3MEQ/L; 140MG/100ML;  
154MG/100ML; 3.5MMOLE/L;  
13MEQ/L; 300MG/100ML;  
147MG/100ML; 40MEQ/L;  
182MG/100ML; 56MG/100ML;  
31MG/100ML; 280MG/100ML
- Aminosyn-pf INJ 46MEQ/L;  
698MG/100ML; 1227MG/100ML;  
527MG/100ML; 820MG/100ML;  
385MG/100ML; 312MG/100ML;  
760MG/100ML; 1200MG/100ML;  
677MG/100ML; 180MG/100ML;  
427MG/100ML; 812MG/100ML;  
495MG/100ML; 3.4MEQ/L;  
70MG/100ML; 512MG/100ML;  
180MG/100ML; 44MG/100ML;  
673MG/100ML
- Aminosyn-pf 7%
- Aprepitant
- Arsenic Trioxide INJ
- Bendeka
- Brovana
- Budesonide SUSP
- Busulfan
- Busulfex
- Cerezyme
- Clinimix 4.25%/dextrose 10%
- Clinimix 4.25%/dextrose 25%
- Clinimix 4.25%/dextrose 5%
- Clinimix 5%/dextrose 15%
- Clinimix 5%/dextrose 20%
- Clinimix 5%/dextrose 25%

- Clinimix E 2.75%/dextrose 10% INJ  
570MG/100ML; 317MG/100ML;  
33MG/100ML; 10GM/100ML;  
283MG/100ML; 132MG/100ML;  
165MG/100ML; 201MG/100ML;  
159MG/100ML; 51MG/100ML;  
110MG/100ML; 454MG/100ML;  
154MG/100ML; 261MG/100ML;  
187MG/100ML; 138MG/100ML;  
217MG/100ML; 112MG/100ML;  
116MG/100ML; 50MG/100ML;  
11MG/100ML; 160MG/100ML
- Clinimix E 4.25%/dextrose 10%
- Clinimix E 4.25%/dextrose 25%
- Clinimix N9g15e
- Clinisol Sf 15%
- Cromolyn Sodium NEBU
- Cubicin
- Cyclophosphamide CAPS
- Cyclophosphamide INJ
- Daptomycin
- Daunorubicin Hydrochloride
- Dextrose INJ 50%
- Dextrose 10%/nacl 0.45%
- Dextrose 5% /electrolyte #48 Viaflex
- Dextrose 10%
- Dextrose 10%/nacl 0.2%
- Dextrose 2.5%/nacl 0.45%
- Dextrose 20%
- Dextrose 25% INJ 250MG/ML
- Dextrose 30%
- Dextrose 40%
- Dextrose 5%/lactated Ringers
- Dextrose 50%
- Duramorph
- Emend SUSR
- Engerix-b
- Etoposide INJ 100MG/5ML,  
1GM/50ML, 500MG/25ML
- Fabrazyme
- Faslodex INJ 250MG/5ML
- Firmagon
- Fludarabine Phosphate
- Folutyn

- Freamine Hbc 6.9%
- Freamine III INJ 89MEQ/L;  
710MG/100ML; 950MG/100ML;  
3MEQ/L; 24MG/100ML;  
1400MG/100ML; 280MG/100ML;  
690MG/100ML; 910MG/100ML;  
730MG/100ML; 530MG/100ML;  
560MG/100ML; 10MMOLE/L;  
120MG/100ML; 1120MG/100ML;  
590MG/100ML; 10MEQ/L;  
400MG/100ML; 150MG/100ML;  
660MG/100ML
- Fulvestrant
- Gamunex-c
- Gemcitabine
- Gemcitabine Hcl
- Gemcitabine Hydrochloride INJ  
1GM, 1GM/26.3ML, 200MG/2ML,  
200MG/5.26ML, 2GM/20ML,  
2GM/52.6ML
- Granisetron Hcl TABS
- Hepatamine
- Hizentra
- Humulin R U-500 (concentrated)
- Imovax Rabies (h.d.c.v.)
- Infugem
- Intralipid INJ 20GM/100ML,  
30GM/100ML
- Ipratropium Bromide INHALATION  
SOLN 0.02%
- Ipratropium Bromide/albuterol  
Sulfate
- Irinotecan INJ 100MG/5ML,  
500MG/25ML
- Irinotecan Hcl
- Irinotecan Hydrochloride
- Kabiven
- Kcl 0.075%/d5w/nacl 0.45%
- Kcl 0.15%/d5w/nacl 0.2%
- Kcl 0.15%/d5w/nacl 0.225% INJ 5%;  
20MEQ/L; 0.225%
- Kcl 0.15%/d5w/nacl 0.45%
- Kcl 0.15%/d5w/nacl 0.9%
- Kcl 0.3%/d5w/nacl 0.45%
- Kcl 0.3%/d5w/nacl 0.9%

- Kyprolis
- Lactated Ringers INJ 3MEQ/L;  
109MEQ/L; 28MEQ/L; 4MEQ/L;  
130MEQ/L
- Lactated Ringers Viaflex
- Magnesium Sulfate INJ  
20GM/500ML, 2GM/50ML,  
40GM/1000ML, 4GM/100ML,  
4GM/50ML, 50%
- Magnesium Sulfate In D5w INJ 5%;  
1GM/100ML
- Melphalan Hydrochloride
- Mesna
- Morphine Sulfate INJ 0.5MG/ML,  
10MG/ML, 150MG/30ML,  
1MG/ML, 2MG/ML, 4MG/ML,  
5MG/ML, 8MG/ML
- Nebupent
- Nephramine
- Normosol -r
- Normosol-m In D5w
- Normosol-r
- Normosol-r In D5w
- Nutrilipid
- Ondansetron Hcl SOLN
- Ondansetron Hcl TABS 24MG
- Ondansetron Hydrochloride TABS
- Ondansetron Odt
- Paclitaxel INJ 100MG/16.7ML,  
150MG/25ML, 300MG/50ML,  
30MG/5ML
- Pamidronate Disodium
- Perforomist
- Perikabiven
- Plenamine
- Potassium Chloride INJ  
10MEQ/100ML, 20MEQ/100ML,  
2MEQ/ML, 40MEQ/100ML
- Potassium Chloride/dextrose INJ 5%;  
20MEQ/L, 5%; 40MEQ/L
- Potassium Chloride/dextrose/lactated  
Ringers
- Potassium Chloride/dextrose/sodium  
Chloride

- Potassium Chloride/sodium Chloride INJ 20MEQ/L; 0.45%, 20MEQ/L; 0.9%, 40MEQ/L; 0.9%
- Prednisone TABS 10MG, 1MG, 2.5MG, 20MG, 50MG, 5MG
- Premasol
- Procalamine
- Prolastin-c
- Prosol
- Pulmozyme
- Rabavert
- Recombivax Hb
- Remodulin
- Ringers Injection INJ 4.5MEQ/L; 156MEQ/L; 4MEQ/L; 147MEQ/L
- Simulect
- Sivextro INJ
- Sodium Lactate INJ 5MEQ/ML
- Temsirolimus
- Tobramycin NEBU
- Toposar INJ 100MG/5ML, 1GM/50ML, 500MG/25ML
- Torisel
- Tpn Electrolytes
- Travasol INJ 52MEQ/L; 1760MG/100ML; 880MG/100ML; 34MEQ/L; 1760MG/100ML; 372MG/100ML; 406MG/100ML; 526MG/100ML; 492MG/100ML; 492MG/100ML; 526MG/100ML; 356MG/100ML; 500MG/100ML; 356MG/100ML; 390MG/100ML; 34MG/100ML; 152MG/100ML
- Treanda INJ 100MG, 25MG
- Treprostinil
- Trisenox INJ 12MG/6ML
- Trogarzo
- Trophamine
- Vincasar Pfs
- Vincristine Sulfate INJ
- Vinorelbine Tartrate
- Vyxeos
- Zoledronic Acid INJ 4MG/5ML, 5MG/100ML

## **Details**

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

# INDEX

<b>A</b>	
Abelcet .....	9
Abiraterone.....	1
Abiraterone Acetate.....	1
Abraxane .....	12
Acetylcysteine .....	152
Acitretin.....	2
Actimmune .....	3
Acyclovir Sodium .....	152
Adagen .....	72
Adempas.....	139
Afinitor .....	95
Afinitor Disperz.....	95
Albuterol Sulfate .....	152
Aldurazyme .....	41
Alecensa .....	95
Alimta.....	4
Aliqopa.....	12
Alosetron .....	5
Alosetron Hydrochloride.....	5
Alunbrig .....	95
Ambisome .....	9
Ambrisentan .....	139
Aminosyn .....	152
Aminosyn II.....	152
Aminosyn M.....	153
Aminosyn-pf.....	153
Aminosyn-pf 7% .....	153
Amitriptyline Hcl .....	67
Amitriptyline Hydrochloride.....	67
Amphotericin B.....	9
Amylin Analog.....	6
Anabolic Steroids, Androgens.....	7
Anadrol-50 .....	7
Antifungals, Azole .....	8
Antifungals, Polyene .....	9
Antifungals, Superficial And Systemic.....	10
Antifungals, Triazole .....	11
Antineoplastics, Monoclonal Antibodies.....	12
Apokyn.....	14
Aprepitant .....	153
Arcalyst.....	15
Arikayce.....	16
Armodafinil.....	102
Arsenic Trioxide .....	153
Austedo .....	17
Avastin .....	12
Avita.....	32
Azathioprine.....	79
<b>B</b>	
Balversa.....	95
Banzel .....	18
Bavencio .....	12
Bendeka.....	153
Benlysta.....	19
Benztropine Mesylate .....	57
Besponsa .....	12
Betaseron.....	81
Bexarotene .....	20
Bortezomib.....	12
Bosentan.....	139
Bosulif.....	95
Botox.....	21
Braftovi .....	95
Brovana .....	153
Brukinsa .....	22
Budesonide.....	153
Buprenorphine.....	23
Buprenorphine Hcl.....	23
Busulfan .....	153
Busulfex .....	153
Butalbital/acetaminophen/caffeine .....	58

<b>C</b>	
Cabometyx .....	95
Calquence .....	95
Caprelsa.....	95
Carbaglu .....	24
Caspofungin Acetate .....	10
Cayston.....	25
Cerezyme.....	153
Chorionic Gonadotropin.....	55
Cinryze .....	26
Clinimix 4.25%/dextrose 10% .....	153
Clinimix 4.25%/dextrose 25% .....	153
Clinimix 4.25%/dextrose 5% .....	153
Clinimix 5%/dextrose 15% .....	153
Clinimix 5%/dextrose 20% .....	153
Clinimix 5%/dextrose 25% .....	153
Clinimix E 2.75%/dextrose 10%.....	154
Clinimix E 4.25%/dextrose 10%.....	154
Clinimix E 4.25%/dextrose 25%.....	154
Clinimix N9g15e.....	154
Clinisol Sf 15% .....	154
Clomipramine Hcl.....	67
Colony Stimulating Factors.....	27
Cometriq.....	95
Copiktra.....	95
Corlanor.....	28
Cotellic .....	95
Cromolyn Sodium .....	154
Cubicin .....	154
Cyclobenzaprine Hydrochloride .....	66
Cyclophosphamide.....	154
Cyclosporine.....	79
Cyclosporine Modified.....	79
Cyramza .....	12
Cystaran.....	29

**D**

Dalfampridine.....	30
Dalfampridine Er.....	30
Daliresp .....	113
Daptomycin .....	154
Darzalex .....	12
Daunorubicin Hydrochloride.....	154
Daurismo .....	95

Demser .....	31
Dermatological Retinoids .....	32
Dermatological Wound Care Agents .....	33
Dextrose .....	154
Dextrose 10%/nacl 0.45%.....	154
Dextrose 5% /electrolyte #48 Viaflex.....	154
Dextrose 10%.....	154
Dextrose 10%/nacl 0.2%.....	154
Dextrose 2.5%/nacl 0.45%.....	154
Dextrose 20%.....	154
Dextrose 25%.....	154
Dextrose 30%.....	154
Dextrose 40%.....	154
Dextrose 5%/lactated Ringers.....	154
Dextrose 50%.....	154
Dihydroergotamine Mesylate.....	34
Dipyridamole .....	63
Dotti .....	59
Doxepin Hcl.....	67
Doxepin Hydrochloride .....	67
Dronabinol .....	35
Duavee .....	36
Dupixent.....	37
Dupixent.....	37
Duramorph .....	154

**E**

Elaprase.....	41
Emend .....	154
Enbrel.....	73
Enbrel Mini .....	73
Enbrel Sureclick.....	73
Endocrine And Metabolic Agents.....	40
Engerix-b.....	154
Enhertu.....	12
Enzyme Replacement/modifiers .....	41
Epclusa.....	42
Epidiolex.....	43
Erivedge .....	44
Erleada .....	45
Erlotinib Hydrochloride .....	95
Esbriet .....	71
Esgic.....	58
Estradiol .....	59
Etoposide.....	154



Everolimus (antineoplastic).....	95
Evomela.....	46
Exjade.....	47
Eylea.....	48

## **F**

Fabrazyme.....	154
Farydak.....	95
Faslodex.....	154
Fentanyl Citrate Oral Transmucosal.....	135
Firmagon.....	154
Fludarabine Phosphate.....	154
Folotyn.....	154
Forteo.....	93
Freamine Hbc 6.9%.....	155
Freamine III.....	155
Fulvestrant.....	155
Fyavolv.....	59
Fycompa.....	49

## **G**

Gamunex-c.....	155
Gattex.....	50
Gazyva.....	12
Gemcitabine.....	155
Gemcitabine Hcl.....	155
Gemcitabine Hydrochloride.....	155
Gengraf.....	79
Genotropin.....	114
Genotropin Miniquick.....	114
Gilenya.....	81
Gilotrif.....	95
Glatiramer Acetate.....	81
Granisetron Hcl.....	155

## **H**

Halaven.....	51
Harvoni.....	52
Hematopoietics.....	53
Hepatamine.....	155
Herceptin.....	12
Herceptin Hylecta.....	12
Hetlioz.....	54
Hizentra.....	155
Hormonal Agents, Gonadotropins.....	55

Hormonal Agents, Somatostatin Analogs.....	56
Hrm - Benztropine.....	57
Hrm - Butalbital Combinations.....	58
Hrm - Estrogens.....	59
HRM - first generation antihistamines.....	60
Hrm - Megestrol.....	61
Hrm - Perphenazine/amitriptyline.....	62
Hrm - Platelet Modifying Agents.....	63
Hrm - Promethazine.....	64
Hrm - Skeletal Muscle Relaxants.....	66
Hrm - Tricyclic Antidepressants.....	67
Humira.....	73
Humira Pediatric Crohns Disease Starter Pack....	73
Humira Pen.....	73
Humira Pen-cd/uc/hs Starter.....	73
Humira Pen-ps/uv Starter.....	73
Humulin R U-500 (concentrated).....	155
Hydroxyprogesterone.....	69
Hydroxyprogesterone Caproate.....	69
Hydroxyzine Hcl.....	60

## **I**

Ibrance.....	95
Icatibant.....	70
Icatibant Acetate.....	70
Iclusig.....	95
Idhifa.....	95
Idiopathic Pulmonary Fibrosis.....	71
Imatinib Mesylate.....	95
Imbruvica.....	95
Imfinzi.....	12
Imipramine Hcl.....	67
Imipramine Hydrochloride.....	67
Immune Stimulants.....	72
Immune Suppressants.....	73
Immune Suppressants - Rinvoq.....	76
Immune Suppressants - Stelara.....	77
Immune Suppressants - Transplant Related.....	79
Immune Suppressants - Xeljanz.....	80
Immunomodulators.....	81
Imovax Rabies (h.d.c.v.).....	155
Increlex.....	85
Infliximab.....	82
Infugem.....	155
Inlyta.....	95

Inrebic.....	95
Insulin-like Growth Factor .....	85
Intralipid.....	155
Ipratropium Bromide.....	155
Ipratropium Bromide/albuterol Sulfate .....	155
Iressa.....	95
Irinotecan.....	155
Irinotecan Hcl.....	155
Irinotecan Hydrochloride .....	155
Istodax .....	86
Istodax (overflow).....	86
Itraconazole .....	10

**J**

Jakafi .....	95
--------------	----

**K**

Kabiven .....	155
Kadcyla.....	12
Kalydeco.....	87
Kanjinti.....	12
Kcl 0.075%/d5w/nacl 0.45%.....	155
Kcl 0.15%/d5w/nacl 0.2%.....	155
Kcl 0.15%/d5w/nacl 0.225%.....	155
Kcl 0.15%/d5w/nacl 0.45%.....	155
Kcl 0.15%/d5w/nacl 0.9%.....	155
Kcl 0.3%/d5w/nacl 0.45%.....	155
Kcl 0.3%/d5w/nacl 0.9%.....	155
Keytruda .....	12
Kisqali .....	95
Kisqali Femara 200 Dose .....	95
Kisqali Femara 400 Dose .....	95
Kisqali Femara 600 Dose .....	95
Korlym .....	88
Kuvan .....	89
Kyprolis.....	156

**L**

Lactated Ringers.....	156
Lactated Ringers Viaflex.....	156
Lartruvo.....	12
Lenvima 10 Mg Daily Dose.....	95
Lenvima 12mg Daily Dose .....	95
Lenvima 14 Mg Daily Dose.....	95
Lenvima 18 Mg Daily Dose.....	95

Lenvima 20 Mg Daily Dose.....	95
Lenvima 24 Mg Daily Dose.....	95
Lenvima 4 Mg Daily Dose.....	95
Lenvima 8 Mg Daily Dose.....	95
Letairis .....	139
Leuprolide Acetate.....	114
Libtayo .....	12
Lidocaine.....	90
Lidocaine Patch.....	90
Lonsurf.....	95
Lorbrena.....	95
Lumizyme .....	91
Lumoxiti.....	12
Lupron Depot (1-month).....	114
Lupron Depot (3-month).....	114
Lupron Depot (4-month).....	114
Lupron Depot (6-month).....	114
Lupron Depot-ped (1-month).....	114
Lupron Depot-ped (3-month).....	114
Lynparza .....	95

**M**

Magnesium Sulfate .....	156
Magnesium Sulfate In D5w .....	156
Mavyret.....	92
Megestrol Acetate .....	61
Mekinist .....	96
Mektovi.....	96
Melphalan Hydrochloride .....	156
Memantine Hcl Titration Pak.....	101
Memantine Hydrochloride .....	101
Memantine Hydrochloride Er .....	101
Mesna.....	156
Metabolic Bone Disease Agents .....	93
Methocarbamol .....	66
Molecular Target Inhibitors .....	94
Monoclonal Antibodies.....	98
Morphine Sulfate .....	156
Mvasi.....	12
Mycophenolate Mofetil.....	79
Mycophenolic Acid Dr .....	79
Mylotarg.....	12

**N**

Naglazyme .....	41
-----------------	----

Natpara .....	99	Perforomist.....	156
Nayzilam .....	100	Perikabiven .....	156
Nebupent .....	156	Perjeta .....	12
Nephramine .....	156	Perphenazine/amitriptyline .....	62
Nerlynx.....	96	Phosphodiesterase Type 4 (pde4) Inhibitors.....	113
Neulasta.....	27	Piqray 200mg Daily Dose.....	96
Neulasta Onpro.....	27	Piqray 250mg Daily Dose.....	96
Nexavar .....	96	Piqray 300mg Daily Dose.....	96
Ninlaro.....	96	Pituitary Hormones .....	114
Nmda Receptor Antagonist.....	101	Plenamaine.....	156
Non-amphetamine Central Nervous System Agents .....	102	Pomalyst.....	96
Norethindrone acetate-estradiol .....	59	Posaconazole Dr.....	11
Normosol -r .....	156	Potassium Chloride .....	156
Normosol-m In D5w .....	156	Potassium Chloride/dextrose .....	156
Normosol-r .....	156	Potassium Chloride/dextrose/lactated Ringers ..	156
Normosol-r In D5w .....	156	Potassium Chloride/dextrose/sodium Chloride..	156
Northera.....	103	Potassium Chloride/sodium Chloride .....	157
Noxafil.....	11	Poteligeo .....	12
Nubeqa .....	114	Prednisone.....	157
Nuedexta.....	104	Premasol.....	157
Nulojix.....	105	Procalamine.....	157
Nuplazid .....	106	Prograf.....	79
Nutrilipid.....	156	Prolastin-c .....	157
<b>O</b>		Promacta .....	115
Ocaliva .....	107	Promethazine Hcl.....	64
Ocrevus.....	108	Promethazine Hcl Plain.....	64
Octreotide Acetate.....	56	Promethazine Hydrochloride .....	64
Odomzo .....	109	Prosol .....	157
Ofev.....	71	Pulmozyme .....	157
Ondansetron Hcl.....	156	Purixan .....	116
Ondansetron Hydrochloride .....	156	<b>Q</b>	
Ondansetron Odt .....	156	Quinine Sulfate .....	117
Opdivo.....	12	Quninie Sulfate .....	117
Orencia .....	110	<b>R</b>	
Orencia Clickject.....	110	Rabavert .....	157
Orkambi.....	111	Rapamune .....	79
Oxandrolone.....	7	Recombivax Hb .....	157
<b>P</b>		Regranex .....	33
Paclitaxel.....	156	Relistor.....	118
Padcev .....	112	Remodulin.....	157
Pamidronate Disodium.....	156	Renflexis .....	82
Part B Versus Part D .....	151	Repatha .....	119
		Repatha Pushtonex System.....	119

Repatha Sureclick.....	119
Retacrit .....	53
Revlimid.....	121
Ringers Injection.....	157
Rinvoq.....	76
Rituxan .....	12
Rituxan Hycela.....	12
Romidepsin.....	86
Rozlytrek .....	122
Rubraca.....	96
Ruconest.....	123
Rydapt .....	96

## **S**

Samsca.....	124
Sandimmune.....	79
Signifor.....	125
Sildenafil Citrate .....	139
Simulect.....	157
Sirolimus .....	79
Sirturo.....	126
Sivextro .....	157
Skyrizi .....	73
Sodium Lactate.....	157
Sodium Phenylbutyrate .....	127
Somatuline Depot.....	56
Somavert.....	40
Sprycel.....	96
Stelara.....	77
Stivarga.....	96
Sutent.....	96
Sylatron .....	128
Symlinpen 120.....	6
Symlinpen 60.....	6
Sympazan .....	129
Synagis .....	130
Synarel.....	114
Synribo .....	96

## **T**

Tacrolimus.....	79
Tafinlar .....	96
Tagrisso .....	96
Talzenna .....	96
Targretin .....	131

Targretin (topical).....	131
Tasigna.....	96
Tecentriq .....	12
Tecfidera .....	81
Tecfidera Starter Pack.....	81
Temsirolimus .....	157
Testosterone .....	7
Testosterone Pump.....	7
Tetrabenazine.....	132
Thalidomide (thalomid) .....	133
Thalomid.....	133
Thiotepa .....	134
Tibsovo .....	96
Tobramycin.....	157
Toposar .....	157
Torisel .....	157
Tpn Electrolytes .....	157
Tracleer .....	139
Transmucosal Fentanyl Citrate .....	135
Travasol.....	157
Treanda .....	157
Trelstar Mixject.....	114
Treprostinil.....	157
Tretinoin.....	32
Tretinoin Microsphere .....	32
Tretinoin Microsphere Pump .....	32
Trimipramine Maleate .....	67
Triptodur .....	114
Trisenox .....	157
Trogarzo .....	157
Trophamine.....	157
Tykerb.....	96
Tymlos .....	93
Tysabri .....	136

## **U**

Unituxin .....	12
Uptravi .....	137

## **V**

Valchlor.....	138
Valchlor Gel.....	138
Vasodilators .....	139
Vectibix.....	12
Velcade .....	12

Venclexta.....	96
Venclexta Starting Pack .....	96
Ventavis.....	140
Verzenio .....	96
Vigabatrin.....	141
Vigadrone .....	141
Vincasar Pfs.....	157
Vincristine Sulfate.....	157
Vinorelbine Tartrate .....	157
Vitrakvi.....	142
Vivitrol .....	143
Vizimpro.....	96
Voriconazole .....	8
Vosevi.....	144
Votrient.....	96
Vyxeos.....	157
<b>X</b>	
Xalkori.....	96
Xatmep .....	145
Xeljanz .....	80
Xeljanz Xr .....	80
Xgeva .....	146
Xiaflex.....	148
Xifaxan .....	147

Xolair .....	98
Xospata .....	96
Xpovio 100 Mg Once Weekly .....	96
Xpovio 60 Mg Once Weekly .....	96
Xpovio 80 Mg Once Weekly .....	96
Xpovio 80 Mg Twice Weekly.....	96
Xtandi.....	96
Xyrem .....	149
<b>Y</b>	
Yervoy.....	12
Yondelis .....	12
<b>Z</b>	
Zarxio .....	27
Zebutal .....	58
Zejula .....	96
Zelboraf.....	96
Zoledronic Acid .....	157
Zortress .....	79
Ztlido.....	150
Zydelig .....	96
Zykadia .....	96
Zytiga .....	96